Catherine Wu
吴修华
MD
Chief, Division of Stem Cell Transplantation and Cellular Therapies; Professor of Medicine, Harvard Medical School干细胞移植与细胞治疗科主任；哈佛医学院医学教授
👥Biography 个人简介
Catherine Wu is a leading oncologist and immunologist at Dana-Farber Cancer Institute and the Broad Institute, widely recognized as a founding architect of the personalized neoantigen cancer vaccine field. Her laboratory pioneered computational neoantigen prediction algorithms and co-developed the NeoVax platform, demonstrating individualized vaccines can elicit durable anti-tumor T cell responses in melanoma and glioblastoma.
🧪Research Fields 研究领域
🎓Key Contributions 主要贡献
Neoantigen Prediction and Vaccine Design Algorithms
Developed foundational computational pipelines for identifying patient-specific somatic mutation-derived neoantigens with predicted HLA-binding affinity, providing the bioinformatic backbone for personalized cancer vaccine programs worldwide.
NeoVax Platform Co-Development
Co-conceived and co-led the NeoVax individualized neoantigen peptide vaccine platform, co-authoring the landmark 2017 Nature phase 1 trial in melanoma and subsequent glioblastoma trials demonstrating vaccine immunogenicity and clinical activity.
Tumor Immunogenomics and Mutation Landscape
Led comprehensive genomic and immunogenomic profiling studies in CLL and other hematologic malignancies, establishing frameworks for understanding how somatic mutations create immunogenic neoantigens exploitable by therapeutic vaccines.
Representative Works 代表性著作
An immunogenic personal neoantigen vaccine for patients with melanoma
Nature (2017)
Co-senior author on first-in-human NeoVax phase 1 trial, demonstrating individualized neoantigen vaccines induce polyfunctional neoepitope-specific T cells and show preliminary clinical efficacy in high-risk melanoma.
Neoantigen vaccine generates intratumoral T cell responses in phase Ib glioblastoma trial
Nature (2019)
Co-senior author demonstrating personalized neoantigen vaccines prime neoantigen-reactive T cells that infiltrate glioblastoma tumors, providing first evidence of CNS tumor immune targeting by individualized vaccines.
Landscape of somatic mutations in 560 breast cancer whole-genome sequences
Nature (2016)
Major contributor to large-scale somatic mutation landscape analysis establishing mutational signatures and neoantigen burden concepts applicable to cancer vaccine target identification.
🏆Awards & Recognition 奖项与荣誉
📄Data Sources 数据来源
Last updated: 2026-01-15 | All information from publicly available academic sources
Related Experts 相关专家
关注 吴修华 的研究动态
Follow Catherine Wu's research updates
留下邮箱，当我们发布与 Catherine Wu（Dana-Farber Cancer Institute / Broad Institute / Harvard Medical School）相关的新研究或访谈时，我们会通知你。
Explore More Experts
Discover the researchers shaping the future of cancer treatment